The Institute of Cancer Research, London and global healthcare company BTG have successfully concluded negotiations with a biopharmaceutical company, Carrick Therapeutics, to take a promising precision drug discovered at The Institute of Cancer Research into a later-stage clinical trial.
InSphero AG today announced that it has successfully completed a collaborative project with the FHNW University in Switzerland to develop a 3D organ-on-a-chip assay for predicting metabolic stability of low clearance compounds in pharmaceutical drug development.
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced the submission of an Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of Tedopi® in advanced or metastatic pancreatic cancer.
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually develop drug resistance, leaving doctors desperate for alternatives.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders
BioDuro LLC, a leading global life sciences contract research and development organization announced today that it has established a new drug discovery center for chemistry and biology in San Diego, CA
In a new report, researchers at the University of York have investigated the ways in which the value of new antimicrobial drugs could be assessed to help the NHS decide how much should be paid for them
Multiple myeloma is a relatively rare type of cancer that develops in the bone marrow – the spongey tissue inside the bone where new blood cells are produced – often spreading to multiple sites within the body
Evotec AG announced recently that it has established an initiative with Sanofi through the launch of a newly created BRIDGE, called LAB031, designed to accelerate drug discovery across multiple therapeutic areas
Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today updates interim overall survival (OS) data from the company’s ongoing Phase 1b clinical trial evaluating CLR 131 for the treatment of relapsed/refractory (R/R) multiple myeloma (MM).
|
|
|
|
|
|
|
|
|